2020
DOI: 10.4266/acc.2020.00038
|View full text |Cite
|
Sign up to set email alerts
|

Direct hemoperfusion with polymyxin B-immobilized fiber column in a patient with acute exacerbation of idiopathic pulmonary fibrosis

Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterized by dyspnea and a worsening of the lung function. Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are defined by a clinically significant respiratory deterioration, that typically develops in less than 1 month, accompanied by new radiologic abnormalities on HRCT, including diffused and bilateral ground-glass opacification, along with an absence of other obvious clinical etiologies. Recently, AE-I… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(3 citation statements)
references
References 13 publications
0
3
0
Order By: Relevance
“…Since AE mortality rates range between 60 and 80% within a 90-day period, most care is strictly palliative in nature [39]. The two primary therapies include corticosteroids like prednisone and cytotoxic medications like cyclophosphamide.…”
Section: Acute Exacerbationsmentioning
confidence: 99%
See 2 more Smart Citations
“…Since AE mortality rates range between 60 and 80% within a 90-day period, most care is strictly palliative in nature [39]. The two primary therapies include corticosteroids like prednisone and cytotoxic medications like cyclophosphamide.…”
Section: Acute Exacerbationsmentioning
confidence: 99%
“…Novel therapy involving administration of polymyxin B-immobilized fiber column (PMX-DHP), originally developed to manage sepsis by removing plasma endotoxins, has shown increased effectiveness [38,42]. One limitation of its use is it can lower white blood cell counts via absorption of neutrophils [38,39]. It remains most effective if administered within 3-7 days of AE onset [38,39].…”
Section: Acute Exacerbationsmentioning
confidence: 99%
See 1 more Smart Citation